Overview

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy. The primary efficacy parameter is percent change in LDL-C after 8 weeks of therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Aegerion Pharmaceuticals, Inc.
Treatments:
Atorvastatin
Atorvastatin Calcium